Phase II Study of Two Weeks on, One Week off Sunitinib Scheduling in Patients With Metastatic Renal Cell Carcinoma

PURPOSE: Standard frontline treatment of patients with metastatic renal cell carcinoma currently includes sunitinib. A barrier to long-term treatment with sunitinib includes the development of significant adverse effects, including diarrhea, hand-foot syndrome (HFS), and fatigue. This trial assessed...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:J Clin Oncol
Autori principali: Jonasch, Eric, Slack, Rebecca S., Geynisman, Daniel M., Hasanov, Elshad, Milowsky, Matthew I., Rathmell, W. Kimryn, Stovall, Summer, Juarez, Donna, Gilchrist, Troy R., Pruitt, Lisa, Ornstein, Moshe C., Plimack, Elizabeth R., Tannir, Nizar M., Rini, Brian I.
Natura: Artigo
Lingua:Inglês
Pubblicazione: American Society of Clinical Oncology 2018
Soggetti:
ORIGINAL REPORTS
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6804828/
https://ncbi.nlm.nih.gov/pubmed/29641297
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2017.77.1485
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi